Immunotherapy with the use of tumor-infiltrating lymphocytes and interleukin-2 as adjuvant treatment in stage III non-small-cell lung cancer

A pilot study

Giovanni B. Ratto, Giovanni Melioli, Paolo Zino, Carlo Mereu, Sandro Mirabelli, Giovanni Fantino, Marco Ponte, Paolo Minuti, Anna Verna, Paolo Noceti, Elisabetta Tassara, Salvatore Rovida

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

This study assesses the feasibility and toxicity of adoptive immunotherapy with tumor infiltrating lymphocytes and recombinant interleukin-2 in 29 patients who underwent resection for stage III non-small-cell lung cancer. In five patients cultures yielded no growth of tumor infiltrating lymphocytes. In the remaining 24 patients (stage IIIa, 14 cases; stage IIIb, 10 cases) tumor infiltrating lymphocytes were in vitro expanded from surgically obtained tissue samples, including samples from both the tumor and surrounding lung. A number of tumor infiltrating lymphocytes, ranging from 4 to 70 billion cells, were reinfused intravenously 4 to 6 weeks after operation. Interleukin-2 was administered subcutaneously at escalating doses for 2 weeks and then at reduced doses for 2 to 3 months. Median survival was 14 months, and the 2-year survival was 40%. Three patients remain alive and disease-free at more than 2 years after operation. Two of these patients did not have complete resection at thoracotomy. Multivariate analysis showed no correlation between the factor of incomplete resection and survival. Intrathoracic recurrence without concomitant distant failure was documented in two patients only and none of the patients with incomplete resection (12 cases) had relapse within the thorax. The present experience demonstrates that adoptive immunotherapy may be applied with safety in patients operated on for stage III non-small-cell lung cancer and suggests that it can be useful, notably in patients with locally advanced disease. (J THORAC CARDIOVASC SURG 1995;109:1212-7).

Original languageEnglish
Pages (from-to)1212-1217
Number of pages6
JournalJournal of Thoracic and Cardiovascular Surgery
Volume109
Issue number6
DOIs
Publication statusPublished - 1995

Fingerprint

Tumor-Infiltrating Lymphocytes
Non-Small Cell Lung Carcinoma
Immunotherapy
Interleukin-2
Adoptive Immunotherapy
Therapeutics
Survival
Recurrence
Feasibility Studies
Thoracotomy
Patient Safety
Thorax
Multivariate Analysis
Lung

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pulmonary and Respiratory Medicine
  • Surgery

Cite this

Immunotherapy with the use of tumor-infiltrating lymphocytes and interleukin-2 as adjuvant treatment in stage III non-small-cell lung cancer : A pilot study. / Ratto, Giovanni B.; Melioli, Giovanni; Zino, Paolo; Mereu, Carlo; Mirabelli, Sandro; Fantino, Giovanni; Ponte, Marco; Minuti, Paolo; Verna, Anna; Noceti, Paolo; Tassara, Elisabetta; Rovida, Salvatore.

In: Journal of Thoracic and Cardiovascular Surgery, Vol. 109, No. 6, 1995, p. 1212-1217.

Research output: Contribution to journalArticle

Ratto, GB, Melioli, G, Zino, P, Mereu, C, Mirabelli, S, Fantino, G, Ponte, M, Minuti, P, Verna, A, Noceti, P, Tassara, E & Rovida, S 1995, 'Immunotherapy with the use of tumor-infiltrating lymphocytes and interleukin-2 as adjuvant treatment in stage III non-small-cell lung cancer: A pilot study', Journal of Thoracic and Cardiovascular Surgery, vol. 109, no. 6, pp. 1212-1217. https://doi.org/10.1016/S0022-5223(95)70205-9
Ratto, Giovanni B. ; Melioli, Giovanni ; Zino, Paolo ; Mereu, Carlo ; Mirabelli, Sandro ; Fantino, Giovanni ; Ponte, Marco ; Minuti, Paolo ; Verna, Anna ; Noceti, Paolo ; Tassara, Elisabetta ; Rovida, Salvatore. / Immunotherapy with the use of tumor-infiltrating lymphocytes and interleukin-2 as adjuvant treatment in stage III non-small-cell lung cancer : A pilot study. In: Journal of Thoracic and Cardiovascular Surgery. 1995 ; Vol. 109, No. 6. pp. 1212-1217.
@article{a8af51e3af6e4c33820c76ce6a734adc,
title = "Immunotherapy with the use of tumor-infiltrating lymphocytes and interleukin-2 as adjuvant treatment in stage III non-small-cell lung cancer: A pilot study",
abstract = "This study assesses the feasibility and toxicity of adoptive immunotherapy with tumor infiltrating lymphocytes and recombinant interleukin-2 in 29 patients who underwent resection for stage III non-small-cell lung cancer. In five patients cultures yielded no growth of tumor infiltrating lymphocytes. In the remaining 24 patients (stage IIIa, 14 cases; stage IIIb, 10 cases) tumor infiltrating lymphocytes were in vitro expanded from surgically obtained tissue samples, including samples from both the tumor and surrounding lung. A number of tumor infiltrating lymphocytes, ranging from 4 to 70 billion cells, were reinfused intravenously 4 to 6 weeks after operation. Interleukin-2 was administered subcutaneously at escalating doses for 2 weeks and then at reduced doses for 2 to 3 months. Median survival was 14 months, and the 2-year survival was 40{\%}. Three patients remain alive and disease-free at more than 2 years after operation. Two of these patients did not have complete resection at thoracotomy. Multivariate analysis showed no correlation between the factor of incomplete resection and survival. Intrathoracic recurrence without concomitant distant failure was documented in two patients only and none of the patients with incomplete resection (12 cases) had relapse within the thorax. The present experience demonstrates that adoptive immunotherapy may be applied with safety in patients operated on for stage III non-small-cell lung cancer and suggests that it can be useful, notably in patients with locally advanced disease. (J THORAC CARDIOVASC SURG 1995;109:1212-7).",
author = "Ratto, {Giovanni B.} and Giovanni Melioli and Paolo Zino and Carlo Mereu and Sandro Mirabelli and Giovanni Fantino and Marco Ponte and Paolo Minuti and Anna Verna and Paolo Noceti and Elisabetta Tassara and Salvatore Rovida",
year = "1995",
doi = "10.1016/S0022-5223(95)70205-9",
language = "English",
volume = "109",
pages = "1212--1217",
journal = "Journal of Thoracic and Cardiovascular Surgery",
issn = "0022-5223",
publisher = "Mosby Inc.",
number = "6",

}

TY - JOUR

T1 - Immunotherapy with the use of tumor-infiltrating lymphocytes and interleukin-2 as adjuvant treatment in stage III non-small-cell lung cancer

T2 - A pilot study

AU - Ratto, Giovanni B.

AU - Melioli, Giovanni

AU - Zino, Paolo

AU - Mereu, Carlo

AU - Mirabelli, Sandro

AU - Fantino, Giovanni

AU - Ponte, Marco

AU - Minuti, Paolo

AU - Verna, Anna

AU - Noceti, Paolo

AU - Tassara, Elisabetta

AU - Rovida, Salvatore

PY - 1995

Y1 - 1995

N2 - This study assesses the feasibility and toxicity of adoptive immunotherapy with tumor infiltrating lymphocytes and recombinant interleukin-2 in 29 patients who underwent resection for stage III non-small-cell lung cancer. In five patients cultures yielded no growth of tumor infiltrating lymphocytes. In the remaining 24 patients (stage IIIa, 14 cases; stage IIIb, 10 cases) tumor infiltrating lymphocytes were in vitro expanded from surgically obtained tissue samples, including samples from both the tumor and surrounding lung. A number of tumor infiltrating lymphocytes, ranging from 4 to 70 billion cells, were reinfused intravenously 4 to 6 weeks after operation. Interleukin-2 was administered subcutaneously at escalating doses for 2 weeks and then at reduced doses for 2 to 3 months. Median survival was 14 months, and the 2-year survival was 40%. Three patients remain alive and disease-free at more than 2 years after operation. Two of these patients did not have complete resection at thoracotomy. Multivariate analysis showed no correlation between the factor of incomplete resection and survival. Intrathoracic recurrence without concomitant distant failure was documented in two patients only and none of the patients with incomplete resection (12 cases) had relapse within the thorax. The present experience demonstrates that adoptive immunotherapy may be applied with safety in patients operated on for stage III non-small-cell lung cancer and suggests that it can be useful, notably in patients with locally advanced disease. (J THORAC CARDIOVASC SURG 1995;109:1212-7).

AB - This study assesses the feasibility and toxicity of adoptive immunotherapy with tumor infiltrating lymphocytes and recombinant interleukin-2 in 29 patients who underwent resection for stage III non-small-cell lung cancer. In five patients cultures yielded no growth of tumor infiltrating lymphocytes. In the remaining 24 patients (stage IIIa, 14 cases; stage IIIb, 10 cases) tumor infiltrating lymphocytes were in vitro expanded from surgically obtained tissue samples, including samples from both the tumor and surrounding lung. A number of tumor infiltrating lymphocytes, ranging from 4 to 70 billion cells, were reinfused intravenously 4 to 6 weeks after operation. Interleukin-2 was administered subcutaneously at escalating doses for 2 weeks and then at reduced doses for 2 to 3 months. Median survival was 14 months, and the 2-year survival was 40%. Three patients remain alive and disease-free at more than 2 years after operation. Two of these patients did not have complete resection at thoracotomy. Multivariate analysis showed no correlation between the factor of incomplete resection and survival. Intrathoracic recurrence without concomitant distant failure was documented in two patients only and none of the patients with incomplete resection (12 cases) had relapse within the thorax. The present experience demonstrates that adoptive immunotherapy may be applied with safety in patients operated on for stage III non-small-cell lung cancer and suggests that it can be useful, notably in patients with locally advanced disease. (J THORAC CARDIOVASC SURG 1995;109:1212-7).

UR - http://www.scopus.com/inward/record.url?scp=0029026383&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029026383&partnerID=8YFLogxK

U2 - 10.1016/S0022-5223(95)70205-9

DO - 10.1016/S0022-5223(95)70205-9

M3 - Article

VL - 109

SP - 1212

EP - 1217

JO - Journal of Thoracic and Cardiovascular Surgery

JF - Journal of Thoracic and Cardiovascular Surgery

SN - 0022-5223

IS - 6

ER -